Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
Open Access
- 1 February 2007
- journal article
- Published by Informa UK Limited in Neuropsychiatric Disease and Treatment
- Vol. 3 (1), 13-39
- https://doi.org/10.2147/nedt.2007.3.1.13
Abstract
To review the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone. Studies published between January 2000 and October 2006 evaluating the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone were reviewed, as identified from literature searches using Medline and EMBASE. Abstracts and posters on long-acting risperidone presented at key psychiatry congresses and available in the public domain during this time period were also reviewed. The unique pharmacokinetic profile of long-acting risperidone is derived from the encapsulation of risperidone in a glycolide/lactide matrix in the form of microspheres such that after a single intramuscular injection, significant plasma levels of the drug are achieved after week 3. Steady state, after repeated administration at 2-week intervals, is achieved after 3 injection cycles. Short- and long-term studies have demonstrated that long-acting risperidone (25, 37.5, or 50 mg) is both efficacious and well tolerated in a wide variety of patients with schizophrenia and related psychoses. Most patients can be switched from other oral and long-acting antipsychotic agents without compromising efficacy and safety. Long-acting risperidone may also reduce overall healthcare costs by decreasing rates of relapse and hospitalization. The assured delivery of an atypical antipsychotic medication with long-acting risperidone has important implications for patient compliance, maintenance of stability, consistency of treatment, and improving patient outcomes including the achievement of remission.Keywords
This publication has 112 references indexed in Scilit:
- Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapineJournal of Psychopharmacology, 2005
- An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term studySchizophrenia Research, 2005
- Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectableJournal of Psychopharmacology, 2005
- Efficacy and safety of long‐acting risperidone in elderly patients with schizophrenia and schizoaffective disorderInternational Journal of Geriatric Psychiatry, 2004
- Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidoneEuropean Psychiatry, 2004
- Current Issues in SchizophreniaCNS Drugs, 2004
- Injections of Depot Antipsychotic Medications in Patients Suffering From SchizophreniaThe Journal of Clinical Psychiatry, 2001
- Pharmacogenetics and psychopharmacotherapyJournal of Clinical Pharmacy & Therapeutics, 2000
- RisperidonePharmacoEconomics, 1998
- Depot Antipsychotic DrugsDrugs, 1994